key: cord-0819342-uwxpip69 authors: Gallais-Serezal, Irène; Puzenat, Eve; Moreau, Joséphine; Dresco, Flora; Pelletier, Fabien; Nardin, Charlée; Aubin, François title: A survey of psoriasis patients on biologics during COVID-19: a high-epidemic area experience – Franche Comté, France date: 2021-05-14 journal: Eur J Dermatol DOI: 10.1684/ejd.2020.3960 sha: 64c9410cd4cd2d5f9a81622ce4112e192903f0ac doc_id: 819342 cord_uid: uwxpip69 nan risk of infection or a more severe disease course [1, 2] . We wish to share our experience in our region (France-Comté [FC]) located in the north east of France, one of the most severely affected by COVID-19. On March 11 th 2020, FC was designated as a "red zone" by the French authorities. During the following two weeks, we sent our patients, by regular mail, the national recommendations which advise to continue the use of biologics during the COVID-19 pandemic. Following this correspondence, we then telephoned all the patients affected by psoriasis and treated with biologic agents to collect data on the use of biologics and COVID-19. Patients with biologics introduced during the study period were excluded. Five hundred and twenty patients followed in our department were called 60 to 65 days after the beginning of the coronavirus epidemic. Response was obtained from 485 patients (93% response rate). All patients who had any COVID-19 symptoms (colds and/or sore throat and/or flu or gastrointestinal symptoms) were asked if they had undergone a swab test. [4] [5] [6] [7] from a high endemic area reported a low number of hospitalizations (<1%) and no intensive care unit admission or death from COVID-19. Furthermore, a recent French study [8] including 1,005 psoriasis patients receiving systemic and biologic treatment found no increased incidence of severe COVID-19 in psoriasis patients during the treatment initiation period compared to those in the maintenance period. However, it should be noted that patients on biologics may have self-isolated more effectively and focused on improved hygiene, thus limiting their own infection risk. In contrast, the international registry PsoProtect [9] , based on 267 clinician-reported psoriasis patients treated with biologics with confirmed/suspected COVID-19 from 25 countries, reported a 16.6% rate of hospitalization and 1.5% rate of death. Although we do not have any clear explanation for this discrepancy, we may suggest a possible selection bias with the over-representation of more severe COVID-19 cases, since these may have been preferentially brought to the attention of clinicians. Altogether, these data do not support the initial suggestion to discontinue all immunosuppressive and biological therapy after exposure to a confirmed COVID-19 case [10] . Even though data from the first wave of COVID-19 support the safety of biologics in patients with psoriasis, it should be remembered that this is a novel, rapidly changing situation; therefore, recommendations may change with additional available data, as this worldwide pandemic is expected to last for months. A case of prurigo caused by hair dye containing p-phenylenediamine: histopathological findings p-phenylenediamine (PPD) is a common allergen among hairdressers and hair dye consumers. Delayed-type IV contact hypersensitivity commonly occurs with PPD exposure, manifesting as eczematous eruptions (e.g., erythema, papules, and vesicles) in localised exposed areas, with subsequent systematised presentation in some cases [1] . Contact allergens, including PPD and metals, may be responsible for prurigo as a clinical expression of allergic contact dermatitis [2, 3] . Although common, neither the histopathology nor molecular mechanisms of PPD-induced prurigo have been elucidated. Herein we report a case of prurigo caused by PPD contained in hair dye and show the histopathological features, including the characteristics of an immune cell infiltrate. A 76-year-old Japanese woman with dyed hair ( figure 1A) presented with a three-year history of itchy rash on her trunk and extremities that was diagnosed as prurigo nodularis or urticaria in other hospitals. The rash was poorly controlled by oral anti-histamine agents, topical steroids, and anti-IgE antibody therapy. Severe itching left her unable to sleep. Physical examination revealed dry skin and multiple, prurigo-like papules with scratch marks spread over her trunk and extremities ( figure 1B-D) . A biopsy was performed on a papule on her lower extremity. The histopathology exhibited hyperkeratosis, acanthosis, and a subcorneal collection of neutrophils, with Epidemiology of urticaria: a representative cross-sectional population survey Chronic urticaria can be caused by cancer and resolves with its cure Chronic urticaria can be caused by cancer and resolves with its cure A systematic review of health-related quality of life reporting in ovarian cancer Phase III clinical trials: room to improve Impact of chronic urticaria on quality of life and work in Japan: results of a real-world study Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Identification of biomarkers for predicting the response to cyclosporine A therapy in patients with chronic spontaneous urticaria Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: infection risk and patient counseling in uncertain times Should biologics for psoriasis be interrupted in the era of COVID-19? COVID-19 and biologics for psoriasis: a high-epidemic area experience -Bergamo A survey of psoriasis patients on biologics during COVID-19: a single centre experience Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19 Factors associated with adverse COVID-19 outcomes in patients with psoriasis -insights from a global registry-based study COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action Acknowledgements and disclosures. Acknowledgements: the patients in this manuscript have given written informed consent to publication of their case details. The authors thank Antoine Calabre, Kathleen Cornec, Antoine Curty, Ulysse Chamboux-Leroux and Elisabeth Homassel for her technical assistance. Conflicts of interest: none.